tofacitinib,TLL-018
pfizer
[]
amazing the chatter in the room for this one. the idea that a new jaki might genuinely outperform existing jaki in hard-to-treat ra, without safety cost, is particularly enticing. we all want to see the paper &amp; healthy skepticism of ph2, but watch this space #eular2023 
Rheumatologist and clinical pharmacologist, world traveller pretences on the upswing, sometimes journal podcast host. All opinions my own